Brief: Fibrogen Initiates Restructuring Plan After Negative Pamrevlumab Clinical Trial Data

Kyntra Bio

07/08/2024 23:00

Aug 7 (Reuters) - FibroGen Inc  FGEN.O :
    * FIBROGEN : INITIATES RESTRUCTURING PLAN AFTER NEGATIVE
PAMREVLUMAB CLINICAL TRIAL DATA
    * FIBROGEN : PLAN TO REDUCE U.S. WORKFORCE BY APPROXIMATELY
75%,
127 EMPLOYEES AFFECTED
    * FIBROGEN INC: ESTIMATES NON-RECURRING CHARGES OF $16-18
MILLION
FOR RESTRUCTURING
    * FIBROGEN : MAJORITY OF RESTRUCTURING CHARGES EXPECTED IN
SECOND
HALF OF 2024

Source text for Eikon:  ID:n0000950170-24-092967 
Further company coverage:  FGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))